Karen E Gieseker1, Emily R Learner2, Kerry Mauk2, Lindley A Barbee3, Candice J McNeil4, Gerald L Hasty5, Jamie M Black6, Kimberly Johnson7, Trang Quyen Nguyen8, Dhana Shrestha9, Cau D Pham2, Sancta St Cyr2, Karen Schlanger2, Robert D Kirkcaldy2. 1. From the Colorado Department of Public Health and Environment, Denver, CO. 2. Centers for Disease Control and Prevention, Atlanta, GA. 3. Department of Medicine, Infectious Diseases, University of Washington, Seattle, WA. 4. Wake Forest University School of Medicine/Guilford County Department of Health, Winston-Salem, NC. 5. Hawaii Department of Health, Honolulu, HI. 6. Indiana Department of Health, Indianapolis, IN. 7. New York City Department of Health and Mental Hygiene, New York, NY. 8. San Francisco Department of Public Health, San Francisco, CA. 9. Milwaukee Health Department, Milwaukee, WI.
Abstract
BACKGROUND: Jurisdictions participating in Strengthening the US Response to Resistant Gonorrhea (SURRG) implemented specimen collection for culture and antimicrobial susceptibility testing from a sample of persons of all genders (at multiple anatomic sites) attending sexually transmitted disease clinics and community clinics. We describe the percentage and characteristics of patients whose isolates demonstrated reduced susceptibility (RS) to azithromycin, ceftriaxone, or cefixime. METHODS: We included patients from clinics that participated in SURRG whose isolates underwent antimicrobial susceptibility testing by Etest. We defined RS as azithromycin minimum inhibitory concentrations (MICs) ≥2 μg/mL (AZM-RS), ceftriaxone MICs ≥0.125 μg/mL (CRO-RS), or cefixime MICs ≥0.25 μg/mL (CFX-RS). Patients with repeated infections appeared >1 time in the data. We calculated the frequency and percentage of patients with an isolate demonstrating RS by epidemiological characteristics. RESULTS: During the period 2018-2019, 10,013 patients from 8 jurisdictions provided 10,735 isolates. Among 10,013 patients, 11.0% (n = 1099) had ≥1 isolate with AZM-RS (range by jurisdiction, 2.5%-18.0%). Approximately 11.3% of 8771 of patients visiting sexually transmitted disease clinics and approximately 8.8% of 1242 patients visiting community clinics had an AZM-RS isolate. Nearly 6% of 1013 females had an AZM-RS isolate; among males, the percents of patients with an AZM-RS isolate were 17.7% among 4177 men who have sex only with men and 6.1% among 3581 men who have sex only with women. Few (0.4%) patients had isolates with CFX-RS (n = 40) or CRO-RS (n = 43). CONCLUSIONS: Although infections with reduced cephalosporin susceptibility were rare, AZM-RS infections were prevalent in this sample of patients in multiple jurisdictions and across gender and gender of sex partner categories.
BACKGROUND: Jurisdictions participating in Strengthening the US Response to Resistant Gonorrhea (SURRG) implemented specimen collection for culture and antimicrobial susceptibility testing from a sample of persons of all genders (at multiple anatomic sites) attending sexually transmitted disease clinics and community clinics. We describe the percentage and characteristics of patients whose isolates demonstrated reduced susceptibility (RS) to azithromycin, ceftriaxone, or cefixime. METHODS: We included patients from clinics that participated in SURRG whose isolates underwent antimicrobial susceptibility testing by Etest. We defined RS as azithromycin minimum inhibitory concentrations (MICs) ≥2 μg/mL (AZM-RS), ceftriaxone MICs ≥0.125 μg/mL (CRO-RS), or cefixime MICs ≥0.25 μg/mL (CFX-RS). Patients with repeated infections appeared >1 time in the data. We calculated the frequency and percentage of patients with an isolate demonstrating RS by epidemiological characteristics. RESULTS: During the period 2018-2019, 10,013 patients from 8 jurisdictions provided 10,735 isolates. Among 10,013 patients, 11.0% (n = 1099) had ≥1 isolate with AZM-RS (range by jurisdiction, 2.5%-18.0%). Approximately 11.3% of 8771 of patients visiting sexually transmitted disease clinics and approximately 8.8% of 1242 patients visiting community clinics had an AZM-RS isolate. Nearly 6% of 1013 females had an AZM-RS isolate; among males, the percents of patients with an AZM-RS isolate were 17.7% among 4177 men who have sex only with men and 6.1% among 3581 men who have sex only with women. Few (0.4%) patients had isolates with CFX-RS (n = 40) or CRO-RS (n = 43). CONCLUSIONS: Although infections with reduced cephalosporin susceptibility were rare, AZM-RS infections were prevalent in this sample of patients in multiple jurisdictions and across gender and gender of sex partner categories.
Authors: Jose A Bazan; Mysheika Williams Roberts; Olusegun O Soge; Elizabeth A Torrone; Amanda Dennison; Melissa Ervin; Sopheay Hun; Karen S Fields; Abigail N Turner Journal: Sex Transm Dis Date: 2018-02 Impact factor: 2.830
Authors: Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi Journal: Sex Health Date: 2019-09 Impact factor: 2.706
Authors: Stephanie A Chisholm; Janet Wilson; Sarah Alexander; Francesco Tripodo; Ali Al-Shahib; Ulf Schaefer; Kieren Lythgow; Helen Fifer Journal: Sex Transm Infect Date: 2015-11-24 Impact factor: 3.519
Authors: Robert D Kirkcaldy; Akbar Zaidi; Edward W Hook; King K Holmes; King H Holmes; Olusegun Soge; Carlos del Rio; Geraldine Hall; John Papp; Gail Bolan; Hillard S Weinstock Journal: Ann Intern Med Date: 2013-03-05 Impact factor: 25.391
Authors: Karen Schlanger; Emily R Learner; Cau D Pham; Kerry Mauk; Matthew Golden; Karen A Wendel; Lori Amsterdam; Candice J McNeil; Kimberly Johnson; Trang Quyen Nguyen; Justin L Holderman; Gerald L Hasty; Sancta B St Cyr; Katy Town; Evelyn E Nash; Robert D Kirkcaldy Journal: Sex Transm Dis Date: 2021-12-01 Impact factor: 2.830
Authors: Sancta St Cyr; Lindley Barbee; Kimberly A Workowski; Laura H Bachmann; Cau Pham; Karen Schlanger; Elizabeth Torrone; Hillard Weinstock; Ellen N Kersh; Phoebe Thorpe Journal: MMWR Morb Mortal Wkly Rep Date: 2020-12-18 Impact factor: 17.586